Global future, page-45

Now for what Lee really said in 2011 before you thank anyone.

Allied has a solid medical product sales business, likely to turn over around $7 million this year according to chief executive Lee Rodne.
The company’s other major asset is a 55 per cent stake in Professor Ian Frazer’s unlisted vaccine developer Coridon.
Prof Frazer is best known for his groundbreaking work on the human papillomavirus vaccine Gardasil, which is sold in Australia and New Zealand by CSL and globally by pharmaceutical giant Merck.
BioMD said today it will offer Allied shareholders 428.3 million shares to close the deal, valuing the Allied at around $38.1 million based on BioMD’s previous trading close of 8.9c.
Allied holders will end up with around 70 per cent of the combined company if the deal is agreed.
Allied’s current major shareholders include Mr Forrest, Clough family company McRae Investments and listed Australian biotech company Avexa. Each of the three major Allied Medical shareholders will end up with around a 17-18 per cent stake in the combined company if the deal goes ahead.